(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...
SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...
High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...
The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.
Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...
Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to clinically meaningful improvement in ...
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...
Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...
The immune checkpoint inhibitor pembrolizumab may reduce this risk. New research findings are summarized in a short video.